Pharmaceutical

Lilly, partner find no Bydureon effect on heart rhythm

June 27, 2011
Bloomberg News
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
More

Lilly diabetes pill recommended for EU approval

June 24, 2011
Bloomberg News
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
More

EU approves Lilly's weekly diabetes drug Bydureon

June 21, 2011
Associated Press
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday.
More

Medco deal loses its luster

June 13, 2011
J.K. Wall
New Jersey-based Medco has hired just 430 workers in Whitestown—far short of its commitment of 1,400 by 2012—and its business trends suggest the company is shrinking, not growing.
More

Lilly enters collaboration deal with Swiss company

June 9, 2011
Associated Press
Drugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop other potential orthopedic treatments.
More

Drug industry outlook negative through 2012, Moody’s says

June 8, 2011
Bloomberg News
Earnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
More

Medco may seek acquisition with biggest contract imperiled

June 7, 2011
Bloomberg News
Medco Health Solutions Inc., which operates a $140 million automated pharmacy and distribution center in Whitestown, has lost $3.5 billion in contracts since March.
More

Lilly licenses Xigris rights to new biotech firm

May 23, 2011
J.K. Wall
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
More

Prescription drug abuse growing problem in Indiana

May 16, 2011
Associated Press
Prescription drugs are playing an increasing role in the drug-related crimes that are filling up Indiana's prisons, prison officials and prosecutors said.
More

Amylin sues Lilly over drug development deal

May 16, 2011
Associated Press
Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.
More

Lilly drug to detect Alzheimer’s criticized by consumer group

May 11, 2011
Bloomberg News
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
More

Two wins to bring Lilly modest sales

May 9, 2011
J.K. Wall
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
More

FDA OKs new diabetes pill from Lilly, Boehringer

May 2, 2011
 IBJ Staff and Associated Press
The Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients who can't control their blood sugar with older medicines.
More

Lilly teams with Medtronic on Parkinson's treatment

April 26, 2011
J.K. Wall
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
More

Wellfount nabs $6M in venture capital

April 19, 2011
The Indianapolis-based institutional pharmacy, which serves long-term-care facilities, wants to expand its business nationally.
More

Analysts demand news on next Lilly blockbuster

April 18, 2011
J.K. Wall
Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.
More

FDA wants further testing of Lilly pancreas drug

April 16, 2011
Associated Press
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
More

Feds: CVS to pay $17.5M over inflated Rx claims

April 15, 2011
Associated Press
The U.S. Justice Department says CVS Pharmacy Inc. has agreed to pay $17.5 million to settle allegations it overcharged Medicaid programs in 10 states, including Indiana.
More

Lilly’s Bydureon wins backing of European drug panel

April 15, 2011
Bloomberg News
The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
More

China making big gains in drug R&D jobs state covets

April 9, 2011
Greg Andrews
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
More

Antidepressants linked to narrowed arteries

April 4, 2011
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based drugmaker.
More

Indiana college to break ground on pharmacy school

April 1, 2011
 IBJ Staff and Associated Press
Northern Indiana's Manchester College plans to begin work this summer on the college's new $18 million pharmacy school.
More

Demographic shift steers Lilly's Asian operations

March 26, 2011
Greg Andrews
China remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic growth.
More

Regulators delay approval of Lilly's Alzheimer’s screen

March 18, 2011
Bloomberg News
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
More

Trade agency to probe Lilly's infringement claim

March 17, 2011
Bloomberg News
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT